| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0006-291X(89)92756-3 |
| P698 | PubMed publication ID | 2575380 |
| P2093 | author name string | Tanaka H | |
| Baba M | |||
| Nakashima H | |||
| Pauwels R | |||
| Perno CF | |||
| De Clercq E | |||
| Schols D | |||
| Walker RT | |||
| Balzarini J | |||
| Miyasaka T | |||
| P433 | issue | 3 | |
| P304 | page(s) | 1375-1381 | |
| P577 | publication date | 1989-12-01 | |
| P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
| P1476 | title | Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative | |
| P478 | volume | 165 |
| Q28379406 | 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity |
| Q28316183 | 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcri |
| Q37784514 | A 40-Year Journey in Search of Selective Antiviral Chemotherapy* |
| Q50043498 | A computational study for rational HIV-1 non-nucleoside Reverse Transcriptase inhibitor selection and discovery of novel allosteric pockets for inhibitor design |
| Q54114811 | A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. |
| Q41058515 | Acyclic nucleosides as antiviral compounds |
| Q44867883 | Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: potential oral iron chelation therapeutics. |
| Q34701036 | Advances in QSAR studies of HIV-1 reverse transcriptase inhibitors. |
| Q26771734 | An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014 |
| Q41346811 | Analysis of inhibition of retroviral reverse transcriptase |
| Q28368003 | Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase |
| Q41121788 | Anti-HIV active naphthyl analogues of HEPT and DABO. |
| Q28328852 | Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives |
| Q56786508 | Antiviral Activity Spectrum of Nucleoside and Nucleotide Analogues |
| Q46860653 | Antiviral activity of 3-(3,5-dimethylbenzyl)uracil derivatives against HIV-1 and HCMV. |
| Q46576605 | Antiviral activity of 4-benzyl pyridinone derivatives as HIV-1 reverse transcriptase inhibitors |
| Q40874319 | Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. |
| Q53320265 | Antiviral research at the Rega Institute (KU leuven), now 50 years old. |
| Q35366050 | Antiviral therapy for human immunodeficiency virus infections |
| Q36070394 | Antiviral therapy: current concepts and practices |
| Q27755387 | Approved Antiviral Drugs over the Past 50 Years |
| Q28378595 | Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217 |
| Q26741313 | Chemical Structure-Biological Activity Models for Pharmacophores' 3D-Interactions |
| Q45858732 | Chemotherapy of the acquired immune deficiency syndrome (AIDS): Non-nucleoside inhibitors of the human immunodeficiency virus type 1 reverse transcriptase |
| Q40060575 | Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2. |
| Q40534064 | Comparative study of non nucleoside inhibitors with HIV-1 reverse transcriptase based on 3D-QSAR and docking |
| Q34163065 | Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding |
| Q38366289 | Curious discoveries in antiviral drug development: the role of serendipity |
| Q38856115 | Design, synthesis, and anti-HIV-1 activity of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives. |
| Q38823843 | Design, synthesis, and anti-HIV-1 activity of 1-substituted 3-(3,5-dimethylbenzyl)triazine derivatives. |
| Q28367707 | Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains |
| Q47576341 | Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors |
| Q41040182 | Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands. |
| Q59352941 | Dynamic Interplay of RNA and Protein in the Human Immunodeficiency Virus-1 Reverse Transcription Initiation Complex |
| Q67466275 | Enzymatic kinetic studies with the non-nucleoside HIV reverse transcriptase inhibitor U-9843 |
| Q42537924 | Evaluation of anti-HIV activity of 5-(2-phenyl-3'-indolal)-2-thiohydantoin |
| Q30884890 | Evolutionary optimization, backpropagation, and data preparation issues in QSAR modeling of HIV inhibition by HEPT derivatives |
| Q40531133 | Fidelity of reverse transcriptase of the simian immunodeficiency virus from African green monkey |
| Q44465623 | Fidelity of the reverse transcriptase of human immunodeficiency virus type 2 |
| Q60304374 | HEPT: From an investigation of lithiation of nucleosides towards a rational design of non-nucleoside reverse transcriptase inhibitors of HIV-1 |
| Q56786269 | HIV Reverse Transcriptase Inhibitors |
| Q40486578 | HIV‐1‐specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase |
| Q43787255 | Hamao Umezawa Memorial Award Lecture: "An Odyssey in the Viral Chemotherapy Field". |
| Q27729427 | High resolution structures of HIV-1 RT from four RT-inhibitor complexes |
| Q28379002 | Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus |
| Q40983879 | Imidazo[1,5-b]pyridazine-d4T conjugates: synthesis and anti-human immunodeficiency virus evaluation |
| Q35375912 | In search of a selective antiviral chemotherapy. |
| Q42275289 | Inhibition of reverse transcriptase of human immunodeficiency virus type 1 and chimeric enzymes of human immunodeficiency viruses types 1 and 2 by two novel non‐nucleoside inhibitors |
| Q43288824 | Looking back in 2009 at the dawning of antiviral therapy now 50 years ago an historical perspective |
| Q27729428 | Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors |
| Q40446517 | Molecular basis and potential activity of HIV-1 reverse transcriptase toward trimethylamine-based compounds |
| Q38458053 | Monte Carlo sampling and multivariate adaptive regression splines as tools for QSAR modelling of HIV-1 reverse transcriptase inhibitors |
| Q40390744 | New developments in the chemotherapy of lentivirus (human immunodeficiency virus) infections: sensitivity/resistance of HIV-1 to non-nucleoside HIV-1-specific inhibitors |
| Q28367654 | New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs |
| Q41153307 | Novel L-lyxo and 5'-deoxy-5'-modified TSAO-T analogs: synthesis and anti-HIV-1 activity. |
| Q44813648 | Nucleoside analogues exerting antiviral activity through a non-nucleoside mechanism |
| Q56786253 | Outlook of the Antiviral Drug Era, Now More Than 50 Years after Description of the First Antiviral Drug |
| Q24316120 | Peptides that bind the HIV-1 integrase and modulate its enzymatic activity--kinetic studies and mode of action |
| Q33631716 | Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection |
| Q28368005 | Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase |
| Q28320362 | Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event |
| Q28323740 | Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase |
| Q28367573 | Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro |
| Q44246955 | QSAR for anti-HIV activity of HEPT derivatives |
| Q28368381 | Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines |
| Q22242815 | Reverse transcription of the HIV-1 pandemic |
| Q28346130 | SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2 |
| Q28342783 | Specific HIV-1 reverse transcriptase inhibitors |
| Q34305893 | Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E |
| Q53526704 | Stereoselective construction of functionalized tetracyclic and pentacyclic coumarinopyranpyrazole/pyrimidinedione/coumarin scaffolds using a solid-state melt reaction. |
| Q43503280 | Structure-activity relationship studies on potential non-nucleoside DABO-like inhibitors of HIV-1 reverse transcriptase |
| Q28333682 | Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro |
| Q56786419 | Synthesis and Antiviral Activity of Novel Fluorinated 2′,3′‐Dideoxynucleosides |
| Q28378262 | Synthesis and HIV-1 inhibitory properties of new tetrahydrobenzoquinazolinedione and tetrahydrobenzocycloheptenuracil derivatives and of their thioxo analogues |
| Q28369722 | Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors |
| Q42744297 | Synthesis and anti-HIV-1 activity of new fluoro-HEPT analogues: an investigation on fluoro versus hydroxy substituents. |
| Q44705799 | Synthesis and antiviral activity of 1,3-disubstituted uracils against HIV-1 and HCMV. |
| Q28377690 | Synthesis and antiviral properties of 9-[(2-methyleneaminoxyethoxy)methyl]guanine derivatives as novel Acyclovir analogues |
| Q59417642 | Synthesis of [1-[3′,5′-Bis-O-(tert-butyldimethylsilyl)-β-d-arabino- and β-d-ribofuranosyl]cytosine]-2′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide). Analogues of the highly specific anti-HIV-1 agent TSAO-T |
| Q35123663 | The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT. |
| Q42278148 | The quinoline U-78036 is a potent inhibitor of HIV-1 reverse transcriptase |
| Q54123440 | The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. |
| Q27732214 | The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design |
| Q40042904 | The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors |
| Q43510541 | The synthesis of novel 6,5- and 6,6-membered fused heterocyclic compounds derived from thymine |
| Q37698440 | The unabated synthesis of new nucleoside analogues with antiviral potential: a tribute to Morris J. Robins |
| Q40637184 | Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses |
| Q36651931 | Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. |
| Q34253409 | Truncated reverse isoxazolidinyl nucleosides: a new class of allosteric HIV-1 reverse transcriptase inhibitors |
| Q27735940 | Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor |
| Q28318473 | [2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1 |
| Q28368045 | Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analo |
Search more.